Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

被引：23

作者：

Lacroix-Desmazes, S ^{[1
]}

Misra, N ^{[1
]}

Bayry, J ^{[1
]}

Artaud, C ^{[1
]}

Drayton, B ^{[1
]}

Kaveri, SV ^{[1
]}

Kazatchkine, MD ^{[1
]}

机构：

[1] Hop Broussais, INSERM, U430, F-75014 Paris, France

来源：

HAEMOPHILIA | 2002年 / 8卷 / 03期

关键词：

factor VIII; FVIII inhibitor; haemophilia; idiotype;

D O I：

10.1046/j.1365-2516.2002.00624.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors. We briefly conclude on the avenues that remain to be explored in order to establish efficient therapeutic approaches aimed at eliminating FVIII inhibitors in patients with haemophilia A.

引用

页码：273 / 279

页数：7

共 50 条

[21] Factor VIII-specific B cell responses in haemophilia A patients with inhibitors
Van Helden, P. M. W.
Van Haren, S. D.
Fijnvandraat, K.
Van Den Berg, H. Marijke
Voorberg, J.
HAEMOPHILIA, 2010, 16 : 35 - 43
[22] Inhibitors in haemophilia: pathophysiology
Saint-Remy, JMR
Lacroix-Desmazes, S
Oldenburg, J
HAEMOPHILIA, 2004, 10 : 146 - 151
[23] Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa
Eichinger, S.
Lubsczyk, B.
Kollars, M.
Traby, L.
Zwiauer, K.
Gleiss, A.
Quehenberger, P.
Kyrle, P. A.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (08) : 707 - 713
[24] Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
Kurth, M. A. H.
Dimichele, D.
Sexauer, C.
Sanders, J. M.
Torres, M.
Zappa, S. C.
Ragni, M.
Leonard, N.
HAEMOPHILIA, 2008, 14 (01) : 50 - 55
[25] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
Pfrepper, Christian
Klamroth, Robert
Ettingshausen, Carmen Escuriola
Petros, Sirak
Siegemund, Annelie
Siegemund, Thomas
HAEMOPHILIA, 2024, 30 (02) : 545 - 553
[26] Factor VIII inhibitors in previously treated haemophilia a patients with a double virus-inactivated plasma derived factor VIII concentrate
Peerlinck, K
Arnout, J
DiGiambattista, M
Gilles, JG
Laub, R
Jacquemin, M
SaintRemy, JMR
Vermylen, J
THROMBOSIS AND HAEMOSTASIS, 1997, 77 (01) : 80 - 86
[27] Factor VIII and IX genotype characterisation of haemophilia patients with transient or permanent inhibitors in Argentina
Rossetti, L.
Szurkalo, I.
Primiani, L.
Neme, D.
Candela, M.
Bianco, R. Perez
HAEMOPHILIA, 2010, 16 : 77 - 77
[28] The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A
Wang, X.
Yang, R.
Zhao, Y.
Wu, J.
Sun, J.
Zhang, X.
HAEMOPHILIA, 2010, 16 : 80 - 80
[29] The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A
Wang, X. F.
Zhao, Y. Q.
Yang, R. C.
Wu, J. S.
Sun, J.
Zhang, X. S.
Ding, Q. L.
Ge, H. L.
Wang, H. L.
HAEMOPHILIA, 2010, 16 (04) : 632 - 639
[30] The in vitro procoagulant effect of recombinant porcine factor VIII in patients with inherited haemophilia A and inhibitors
Dargaud, Yesim
Nougier, Christophe
Desage, Stephanie
Meunier, Sandrine
Lienhart, Anne
HAEMOPHILIA, 2022, 28 : 40 - 41

← 1 2 3 4 5 →